|MDACC Study No:||2012-0107 (clinicaltrials.gov NCT No: NCT01456689)|
|Title:||A multi-center, open-label, dose escalation, Phase 1 study of oral LGH447 in patients with relapsed and/or refractory multiple myeloma|
|Principal Investigator:||Sheeba K. Thomas|
|Study Description:||The goal of this clinical research study is to learn the highest tolerable dose |
of LGH447 that can be given to patients with MM. The safety of the drug will
also be tested.
LGH447 is designed to block proteins that are thought to cause cancer cells to
This is the first study using LGH447 in humans.